British Peripheral Nerve Society

This meeting is open to BPNS members and other professionals working in relevant areas, but not to patients or members of the general public without advance permission.
BPNS members wishing to register for the meeting may benefit from a reduced registration fee if they log in to the website first.

BPNS Spring Meeting 2022: virtual

Start Date

End Date

Friday 11 Mar 2022 09:00 AM

Friday 11 Mar 2022 16:30 PM

Location

Zoom meeting hosted by Manchester

Details

The Spring Meeting of the BPNS will be the usual mix of case presentations, invited lectures and a discussion forum.

We welcome Professor Riyaz Malik of the University of Manchester as keynote speaker.

We welcome submitted abstracts for case presentations via the website.

There will be a open discussion forum on the Investigation and Management of Small Fibre Polyneuropathy

The full programme will be announced in full at a later date.

Submit an abstract for consideration

Programme

Time	Type		Presenter
09:00	Registration	See under the F2F meeting for the programme!

Event price

£35.00

Tickets requested

1 public ticket @ £35.00

Full name

Email address

Occupational Group

Professional Reg No. (if applicable e.g. GMC, GPHC)

If you are a member, please login to ensure your booking is linked to your account and you get the best available prices.

Do you have any special requirements? e.g. Wheelchair access

IMPORTANT! You must return to the BPNS website after paying for your event tickets in order for your booking to be properly registered. If PayPal does not automatically redirect you, then please click the 'return to merchant' link after successful payment. If your paypal payment fails then the BPNS website may show you as registered for the meeting for the next hour or so. Please wait a few hours and then try again to register.

New NHSE commissioning policies for rituximab and IVIg

We are pleased to announce that, largely due to the efforts of our president Prof Lunn, rituximab is now approved for treatment of IgM paraproteinaemic demyelinating peripheral neuropathy (anti-MAG phenotype, with or without anti-MAG antibodies): 1910-rituximab-for-treatment-of-PDPN-policy-v2.pdf (england.nhs.uk). Whilst we have hitherto been able to treat some patients with rituximab by sending them to a haematologist, this was not possible if the bone marrow showed insufficient evidence of underlying lymphoplasmacytic lymphoma. These patients can now be treated, regardless of bone marrow result, either by you or by your friendly haematologist, under the new commissioning guidance.
Also thanks to Prof Lunn (alongside non-neurology colleagues), the updated IVIg commissioning policy is now available: Commissioning-Criteria-Policy-for-the-use-of-Ig-Version-Finala.pdf (mdsas.com). Newly commissioned diagnoses of relevance to peripheral nerve now include acute autoimmune autonomic ganglionopathy, and neuromyotonia.
Finally, with thanks largely to the efforts of Dr Rinaldi in Oxford, rituximab can now be used for the treatment of autoimmune nodopathies (with nodal/paranodal antibodies): NHS England » Rituximab therapy for the treatment of nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.

Kings Neuromuscular Symposium 2022

This annual event will take place as an online video webinar. Friday 28th January 2022. Registration Link

GWAS study of CIDP

Members are encouraged to participate in a genome-wide association study of CIDP. Brief details can be found HERE

COVID Vaccination and GBS

Following on from the successful BPNS instigated study of GBS linked to COVID-19 infection - whhich found no evidence that COVID is a significant trigger for GBS, te society is now encouraging a similar collaborative study of GBS following COVID vaccination (any vaccine). Details can be found in the members pages - HERE (login to access)

More news »

Meetings

New NHSE commissioning policies for rituximab and IVIg

Kings Neuromuscular Symposium 2022

GWAS study of CIDP

COVID Vaccination and GBS